COVID-19 in Patients With Pre-existing Cirrhosis (COVID-Cirrhosis-CHESS2002): A Multicentre Observational Study
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT04329559 |
Recruitment Status :
Completed
First Posted : April 1, 2020
Last Update Posted : February 24, 2021
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease |
---|
COVID-19 Liver Cirrhosis |
Study Type : | Observational [Patient Registry] |
Actual Enrollment : | 21 participants |
Observational Model: | Cohort |
Time Perspective: | Cross-Sectional |
Target Follow-Up Duration: | 1 Year |
Official Title: | Clinical Characteristics of COVID-19 in Patients With Pre-existing Cirrhosis (COVID-Cirrhosis-CHESS2002): A Multicentre Observational Study |
Actual Study Start Date : | March 30, 2020 |
Actual Primary Completion Date : | February 10, 2021 |
Actual Study Completion Date : | February 10, 2021 |

- All-cause mortality of COVID-19 patients with liver cirrhosis [ Time Frame: From illness onset of COVID-19 to death from any cause, up to 365 days ]7-day, 28-day, 60-day, 180-day and 365-day all-cause mortality of COVID-19 patients with liver cirrhosis
- Liver-related mortality of COVID-19 patients with liver cirrhosis [ Time Frame: From illness onset of COVID-19 to death from liver-related cause, up to 365 days ]7-day, 28-day, 60-day, 180-day and 365-day liver-related mortality of COVID-19 patients with liver cirrhosis
- Risk factors associated with specific outcomes of COVID-19 patients with liver cirrhosis [ Time Frame: From hospital admission to death, up to 365 days ]Risk factors (laboratory findings, imaging findings, etc.) associated with specific outcomes (death, etc.) of COVID-19 patients with liver cirrhosis
- Baseline characteristics of COVID-19 patients with liver cirrhosis [ Time Frame: 1 Day ]Baseline characteristics (laboratory findings, imaging findings, etc.) of COVID-19 patients with liver cirrhosis

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Sampling Method: | Non-Probability Sample |
Inclusion Criteria:
- 1) Aged 18 or above;
- 2) Laboratory-confirmed COVID-19 infection;
- 3) Pre-existing liver cirrhosis based on liver biopsy or clinical findings.
Exclusion Criteria:
- 1) Pregnancy or unknown pregnancy status.

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04329559
China | |
Dalian Sixth People's Hospital | |
Dalian, China | |
Minda Hospital Affiliated to Hubei University for Nationalities | |
Enshi, China | |
The Central Hospital of Enshi Tujia And Miao Autonomous Prefecture | |
Enshi, China | |
The First Hospital of Lanzhou University | |
Lanzhou, China | |
The Central Hospital of Lishui City | |
Lishui, China | |
Guangxi Zhuang Autonomous Region | |
Nanning, China | |
The Sixth Peoples Hospital of Shenyang | |
Shenyang, China | |
Shenzhen Third People's Hospital | |
Shenzhen, China | |
Suizhou Hospital, Hubei University of Medicine | |
Suizhou, China | |
Tianjin Second People's Hospital | |
Tianjin, China | |
Ankang Central Hospital | |
Wuhan, China | |
Renmin Hospital of Wuhan University | |
Wuhan, China | |
Wuhan Union Hospital | |
Wuhan, China | |
Xingtai People's Hospital | |
Xingtai, China | |
The Affiliated Third Hospital of Jiangsu University | |
Zhenjiang, China |
Study Chair: | Mingkai Chen, MD | Renmin Hospital of Wuhan University | |
Study Chair: | Xiaolong Qi, MD | LanZhou University | |
Principal Investigator: | Fengmei Wang, MD | Tianjin Second People's Hospital | |
Principal Investigator: | Ye Gu, MD | The Sixth People's Hospital of Shenyang | |
Principal Investigator: | Zicheng Jiang, MD | Ankang Central Hospital | |
Principal Investigator: | Guo Zhang, MD | Guangxi Zhuang Autonomous Region | |
Principal Investigator: | Yong Zhang, MD | Dalian Sixth People's Hospital | |
Principal Investigator: | Dengxiang Liu, MD | Xingtai People's Hospital | |
Principal Investigator: | Qing He, MD | Shenzhen Third People's Hospital | |
Principal Investigator: | Hua Yang, MD | Minda Hospital Affiliated to Hubei University for Nationalities | |
Principal Investigator: | Zhengyan Wang, MD | Suizhou Hospital, Hubei University of Medicine | |
Principal Investigator: | Bin Xiong, MD | Wuhan Union Hospital, China | |
Principal Investigator: | Xiaodan Li, MD | The Central Hospital of Enshi Tujia And Miao Autonomous Prefecture | |
Principal Investigator: | Hongguang Zhang, MD | The Affiliated Third Hospital of Jiangsu University | |
Principal Investigator: | Chuxiao Shao, MD | The Central Hospital of Lishui City | |
Principal Investigator: | Hongmei Yue, MD | LanZhou University |
Responsible Party: | Xiaolong Qi, Chief, Institute of Portal Hypertension, Hepatopancreatobiliary Surgery Institute of Gansu Province |
ClinicalTrials.gov Identifier: | NCT04329559 |
Other Study ID Numbers: |
CHESS2002 |
First Posted: | April 1, 2020 Key Record Dates |
Last Update Posted: | February 24, 2021 |
Last Verified: | February 2021 |
Individual Participant Data (IPD) Sharing Statement: | |
Plan to Share IPD: | Undecided |
Studies a U.S. FDA-regulated Drug Product: | No |
Studies a U.S. FDA-regulated Device Product: | No |
COVID-19 Liver cirrhosis Clinical outcome |
COVID-19 Liver Cirrhosis Fibrosis Respiratory Tract Infections Infections Pneumonia, Viral Pneumonia Virus Diseases Coronavirus Infections |
Coronaviridae Infections Nidovirales Infections RNA Virus Infections Lung Diseases Respiratory Tract Diseases Pathologic Processes Liver Diseases Digestive System Diseases |